La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Arcutis Biotherapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Arcutis Biotherapeutics..

Arcutis Biotherapeutics (NASDAQ:ARQT) Azioni, Catena delle Opzioni

ARCUTIS BIOTHERAPEUTICS INC

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Elevate,Healthcare,With,Ai,Technology,Services.virtual,Health,Care,Analytics,Empower

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ARQT

TNXP

L&#39;analisi tecnica rivela segnali di allarme per queste società: cosa devono aspettarsi gli investitori e perché è importante agire.

2 titoli del settore sanitario che potrebbero crollare questo trimestre

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics Inc

Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) has outperformed the market over the past 15 years by 1.71% on an annualized basis producing an average annual return of 12.57%. Currently, Royal Caribbean Gr has a market capitalization of $55.29 billion. 
Buying $100 In RCL: If an investor had bought $100 of RCL stock 15 years ago, it would be worth $596.52 today based on a price of $205.44 for RCL at the time of writing.
<h3>Royal Caribbean Gr's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743457513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Royal Caribbean Gr 15 Years Ago Would Be Worth This Much Today

Also concurrent with the Transaction, the Board has named two new Directors, who will replace seats vacated by Edward Forst and Jennifer Carr-Smith. &nbsp;

Management

LOCL

Local Bounti Says It Secured $25M Investment From New And Existing Investors In March 2025; Craig Hurlbert Steps Into New Role As Executive Chairman, Kathleen Valiasek Named As CEO

The anticipated revenue growth is expected to increase gross profits by an estimated $1.4 million for fiscal year 2025.&nbsp;

Guidance

XPON

Expion360 Anticipates New OEM Partnerships And Distributors To Generate Incremental Revenue Of $5M For FY25

Soho House (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $0.03 by 1666.67 percent. The company reported quarterly sales of $305.55 million which missed the analyst consensus estimate of $318.36 million by 4.02 percent. This is a 5.08 percent increase over sales of $290.79 million the same period last year.

Earnings

Earnings Misses

SHCO

Soho House Q4 2024 Sales $305.55M Miss $318.36M Estimate

The Company's Class A common stock will begin trading on a reverse-split-adjusted basis when the markets open on April 3, 2025.&nbsp;

Stock Split

MKTW

MarketWise Plans To Effect 1-For-20 Reverse Stock Split Of Its Common Stock

<a href="https://www.youtube.com/watch?v=vqR9UibseME" title="https://www.youtube.com/watch?v=vqR9UibseME">https://www.youtube.com/watch?v=vqR9UibseME</a>

Events

INTC

Intel CEO Lip-Bu Tan, Speaking At  Intel Vision 2025, Said Company Will Spin Off Non-Core Businesses, Plans To Develop Custom Silicon For Specific Applications

CaliberCos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.04) by 1175 percent. This is a 363.64 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $8.69 million which beat the analyst consensus estimate of $6.69 million by 29.85 percent. This is a 63.72 percent decrease over sales of $23.95 million the same period last year.

Earnings Beats

CaliberCos Q4 2024 GAAP EPS $(0.51) Misses $(0.04) Estimate, Sales $8.69M Beat $6.69M Estimate

CPI Aerostructures Q4 EPS, Excluding Deferred Tax Asset Valuation Impact, $0.11 Up From $0.05 YoY, Sales $21.8M Down From $23.5M YoY

The Ordinary Shares have been approved for listing on the NASDAQ Capital Market and are expected to commence trading on April 1, 2025, under the ticker symbol "ENGS."

IPOs

Energys Group Prices IPO Of 2.25M Ordinary Shares At $4.50 Per Ordinary Share

Banco Macro Appoints Juan Parma As Its New CEO

Maui Land & Pineapple 2024 EPS $(0.38) Down From $(0.15) YoY, Sales $11.56M Up From $9.29M YoY

These certifications will enable Springview Singapore to bid for small-scale public sector projects and the Company therefore expects that these certifications will allow Springview Singapore to significantly expand its addressable market.

SPHL

Springview's Singapore Subsidiary Secures Two New Important Government Certifications

GCTK

Glucotrack 2024 EPS $(68.44) Down From $(34.18) YoY

Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 20 years by 5.89% on an annualized basis producing an average annual return of 13.93%. Currently, Union Pacific has a market capitalization of $141.58 billion. 
Buying $1000 In UNP: If an investor had bought $1000 of UNP stock 20 years ago, it would be worth $13,730.89 today based on a price of $236.24 for UNP at the time of writing.
<h3>Union Pacific's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743455708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) reported quarterly losses of $(0.01) per share. This is a 75 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $113.39 million which beat the analyst consensus estimate of $91.88 million by 23.41 percent. This is a 8.43 percent increase over sales of $104.58 million the same period last year.

MVST

Microvast Holdings Q4 2024 Adj EPS $(0.01) Up From $(0.04) YoY, Sales $113.39M Beat $91.88M Estimate

REBN

Reborn Coffee Q4 Sales $1.8M Up From $1.4M YoY

Seritage Growth Properties Q4 EPS $(0.22) Down From $0.08 YoY

FCX currently expects its consolidated copper sales for first-quarter 2025 to be in line with its January 2025 guidance of 850 million pounds and its gold sales for first quarter 2025 to be approximately 100 thousand ounces below its January 2025 guidance of 225 thousand ounces.
FCX is reviewing its annual consolidated sales guidance in connection with its routine quarterly forecast updates and does not currently expect a material change to its 2025 annual guidance.
 &nbsp;
 &nbsp;

Freeport Says Q1 Copper And Gold Production Approximated Expectations; Expects No Material Impact On Annual Consolidated Sales Guidance

<h3>Gainers</h3>
<ul>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock increased by 37.5% to $0.4 during Monday's after-market session. The company's market cap stands at $2.7 million. </li>
<li>Sportsman's Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) stock rose 15.68% to $1.15. The market value of their outstanding shares is at $43.6 million. </li>
<li>PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) stock moved upwards by 15.51% to $74.67. The market value of their outstanding shares is at $4.1 billion. The company's, Q4 earnings came out today. </li>
<li>Lazydays Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) stock increased by 14.05% to $0.37. The company's market cap stands at $40.6 million. As per the press release, Q4 earnings came out today. </li>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) shares increased by 11.66% to $0.33. The market value of their outstanding shares is at $6.1 million. </li>
<li>Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) shares moved upwards by 10.66% to $0.19. The market value of their outstanding shares is at $10.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LightInTheBox Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NYSE">LITB</a>) stock declined by 14.5% to $1.71 during Monday's after-market session. The company's market cap stands at $190.0 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>Interactive Strength (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) stock declined by 10.57% to $1.1. The market value of their outstanding shares is at $1.6 million. </li>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 9.51% to $1.9. The company's market cap stands at $511.8 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares declined by 6.77% to $0.66. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) stock fell 6.67% to $0.1. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) stock fell 6.24% to $3.01. The company's market cap stands at $17.9 million. As per the news, the Q4 earnings report came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALUR

CLEU

GORV

LITB

MKDW

MULN

SBET

SPWH

TRNR

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 198.8% to $0.78 during Monday's after-market session. The company's market cap stands at $12.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares rose 51.02% to $70.3. The company's market cap stands at $382.2 million. As per the press release, Q4 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock rose 18.42% to $2.25. The company's market cap stands at $309.5 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock moved upwards by 17.7% to $1.13. The market value of their outstanding shares is at $6.6 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 16.29% to $3.24. The market value of their outstanding shares is at $8.8 million. As per the press release, Q4 earnings came out today. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares moved upwards by 10.48% to $0.55. The market value of their outstanding shares is at $9.3 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock fell 11.2% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares declined by 8.9% to $2.51. The company's market cap stands at $3.7 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 8.61% to $0.85. The market value of their outstanding shares is at $60.8 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock declined by 7.83% to $0.34. The market value of their outstanding shares is at $17.8 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares decreased by 6.67% to $0.56. The market value of their outstanding shares is at $2.5 million. </li>
<li>Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) stock declined by 6.64% to $4.08. The market value of their outstanding shares is at $84.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVM

BIAF

BNGO

CMPX

CTOR

EVOK

NUTX

PSTV

TLPH

12 Health Care Stocks Moving In Monday's After-Market Session

Press Releases

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Health Care

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

General

U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

Comments

Arcutis Biotherapeutics

Arcutis Biotherapeutics (ARQT) Opzioni

Arcutis Biotherapeutics (NASDAQ:ARQT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO